newsfilter
← Latest News
Business Wire·

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

  • AN2 Therapeutics received a funding extension from the Gates Foundation to support its tuberculosis research collaboration with GSK.
  • The funding will advance boron-based leucyl-tRNA synthetase (LeuRS) inhibitors for the treatment of tuberculosis.
  • Tuberculosis remains a leading global infectious disease killer, with an estimated 10.7 million cases reported in 2024.
  • AN2's boron chemistry platform targets LeuRS, a validated target also associated with drugs such as epetraborole, ganfeborole, & tavaborole.
  • GSK & AN2 Therapeutics remain committed to developing new treatment options to address the urgent global need for tuberculosis therapies.
  • AN2 Therapeutics plans to have three Phase 2 studies active in 2026 across hematologic diseases, infectious diseases, & oncology.
  • The press release includes forward-looking statements regarding the potential success of the collaboration & future clinical trial outcomes.